R&D | May 25, 2026
AbbVie signals major oncology momentum at ASCO
With standout ADC and t-cell engager response data across hard-to-treat cancers
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Surya to lead medical governance, patient safety, clinical excellence, and quality assurance initiatives across the organization’s pan-India network.
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
Subscribe To Our Newsletter & Stay Updated
